Presentation is loading. Please wait.

Presentation is loading. Please wait.

Acute HIV and the North Carolina STAT Project Past, Present and Future Peter Leone, MD Associate Professor of Medicine University of North Carolina Medical.

Similar presentations


Presentation on theme: "Acute HIV and the North Carolina STAT Project Past, Present and Future Peter Leone, MD Associate Professor of Medicine University of North Carolina Medical."— Presentation transcript:

1 Acute HIV and the North Carolina STAT Project Past, Present and Future Peter Leone, MD Associate Professor of Medicine University of North Carolina Medical Director North Carolina HIV/STD Prevention and Care

2 ACBD 7/28/05 Develops HA, Fever Went to ER, LP, labs DX: RMSF, doxycycline given Symptoms worsen 2 Days later admitted HIV Ab neg Discharge Aseptic meningitis Possible RMSF 8/15/05-8/30/05 A&B: Sex 3-4x 8/30/05 A,B,C: 3-way 9/10/05 Develops fever, ST, fatigue Local PMD gives Z-pack Partners B&C steady Sex 1-2x/wk 10/15/05 B,C,D have 3-way 9/30/05 Develops fever, LAD,ST Local PMD gives Z-pack 10/28/05 Develops fever, ST, oral ulcers, thrush Antibiotics given Requests HIV test

3 ACB D 11/15/05 HIV+ (ELISA + WB: I)

4 A C B D 11/15/05 HIV+ (ELISA + WB: I) 12/1/05 HIV+ 12/1/05 HIV+

5 A C B D 11/15/05 HIV+ (ELISA + WB: I) 12/1/05 HIV+ 12/1/05 HIV+ 12/20/05 HIV+

6 A C B D 11/15/05 HIV+ (ELISA + WB: I) 12/1/05 HIV+ 12/1/05 HIV+ 12/20/05 HIV+ 5 infections could have been avoided if acute HIV infection considered at first presentation

7 Definition of Acute HIV Infection Time period following infection with HIV during which HIV virus can be detected in blood but antibodies to HIV are not Time period following infection with HIV during which HIV virus can be detected in blood but antibodies to HIV are notOR Window period when routine HIV antibody tests (EIAs) are negative but HIV virus can be detected in blood Window period when routine HIV antibody tests (EIAs) are negative but HIV virus can be detected in blood

8 Primary HIV Infection Definition: Acute HIV infection + recent infection with HIV. Definition: Acute HIV infection + recent infection with HIV. Recent Infection: patients who are positive on HIV antibody testing (EIA), but have one of the following: Recent Infection: patients who are positive on HIV antibody testing (EIA), but have one of the following: –A recent prior negative HIV test or –Results of detuned antibody test suggesting recent infection.

9 Couthino et al., Bulletin of Mathematical Biology 2001

10 Detecting Acute HIV Infections Symptoms p24 Antigen HIV RNA HIV Ab Tests Weeks Since Infection

11 PCR Testing of Pooled Sera to Identify Acute HIV Infection (seronegative, PCR positive) Source: ISSTDR, 2007

12 How do we pick-up Acute HIV infection if routine antibody tests are negative?

13 Acute Retroviral Syndrome 40-90% of new HIV infections are symptomatic 40-90% of new HIV infections are symptomatic Signs and symptoms typically begin 1-4 weeks following the exposure Signs and symptoms typically begin 1-4 weeks following the exposure Symptoms can last from days to several weeks, but usually <14 days Symptoms can last from days to several weeks, but usually <14 days Pilcher C et al. N Engl J Med 2005;352: Kahn JO, Walker BD. N Engl J Med. 1998;339:33-39 Schacker T, et al. Ann Intern Med. 1996;125:

14 Acute HIV Incubation Periods Days from Sexual Exposure to Onset of Symptoms Frequency Patients Average = 14 days Range: 5-30 days Sources: Pilcher, JAMA 2001; Borrow, Nat Med 1997; Schacker AIM 1996; Lindback, AIDS 2001

15 Non-specific Mononucleosis-like Signs and Symptoms Fever Fever Rash Rash Oral ulcer Oral ulcer Weight loss Weight loss Loss of appetite Loss of appetite Headache Headache Fatigue Fatigue Adenopathy Adenopathy Sore throat/ pharyngitis Sore throat/ pharyngitis Muscle and/or joint pain Muscle and/or joint pain Diarrhea Diarrhea GI upset/nausea/ GI upset/nausea/ vomiting vomiting

16 Common Signs & Symptoms Vanhems P et al. AIDS 2000; 14: % of patients Study of 160 patients with primary HIV infection in 3 countries

17 Acute HIV and Symptoms Schacker Kinloch-de Loes NC STD Fever93%87% 48% Fatigue Pharyngitis Headache Rash 15 GI Symptoms 37 Schacker TW, et al., AIM :257-64

18 Common Mis-diagnoses Mononucleosis Mononucleosis Rocky Mountain Spotted Fever Rocky Mountain Spotted Fever Strep throat Strep throat Influenza Influenza Viral illness Viral illness Secondary syphilis Secondary syphilis

19 Primary HIV Infection: Pathogenesis Plasma HIV RNA CD4 Cell Count 4-8 WeeksUp to 12 Years2-3 Years CD4 Cell Count (cells/mm³) Symptoms PrimaryHIV ProgressionAIDS

20 How do we pick-up Acute HIV infection if patients dont have symptoms?

21 Our approach to Screening for AHI Specimen pooling Advantages Advantages Seamless (almost) incorporation into HIV testing Seamless (almost) incorporation into HIV testing Reduced cost No real change in specificity Universal application Disadvantages Disadvantages Requires large testing volume Small loss in sensitivity Logistics Time to Dx and locating patient

22 STAT Testing Protocol Acute HIVHIV Negative HIV Positive EIA/ Western Blot HIV RNA testing F/U Testing (Ab + HIV RNA)

23 Pooling and HIV RNA testing 90 individual HIV antibody negative specimens 9 intermediate pools (10 specimens) 1 master pool (90 specimens)

24 Distribution of Viral Loads in Ab Negative VCT Specimens NC Testing Data (n=58) n log HIV RNA cp/ml

25 Low viral load specimens n log HIV RNA cp/ml

26 STAT Case Possible acute HIV Infection STAT Case Possible acute HIV Infection Confirmatory Test HIV Antibody and RNA Testing Confirmatory Test HIV Antibody and RNA Testing DIS Interview Referral to Care DIS Interview Referral to Care Contact < 72 hrs Contact < 8 weeks Contact > 8 weeks STAT Post-Exposure Protocol STAT Contact Protocol STAT Contact Protocol Routine Partner Notification Protocol Routine Partner Notification Protocol EIA or Ab(-) EIA/Ab (+) and WB (+) or EIA/Ab (-) RNA (+) Confirmed Acute HIV + STAT Notification Confirmed Acute HIV + STAT Notification Immediate contact Dr. Leone UNC ID – on call Immediate contact Dr. Leone UNC ID – on call Repeat Testing EIA or Ab (+) False RNA Positive False RNA Positive Ab - STAT Index Case Protocol

27 Notification of AHI in STAT Time to notification improved to ~11 days from the time of testing (est. ~39D into 80D hyper-infectious period)

28 The STAT System State Laboratory Laboratory Identification Disease Intervention Specialist Team Notification, Interviews, Confirmatory Testing, Transportation to Clinic UNC Weekly Case- Conference (Surveillance, Lab, DIS, UNC Evaluation Teams) Data collection UNC/Duke Collaborative Free Urgent clinical evaluation Recruitment to studies UNC Acute HIV Program Research Database UNC Specimen Repository -surveillance/research testing

29 Screening and Tracing Active Transmission (STAT) Program From , 79 cases identified –3 not located –1 refusal for PCRS 269 partners (from 75 AHI patients) identified within an 8-week exposure window –174 (65%) named 132 (76%) located –95 (35%) anonymous

30 STAT PCRS Outcomes ( ) 46% (80) Counseled & Tested

31 Why focus on Acute HIV Infection?

32 HIV Epidemic in NC 7th leading cause of death for men and women ages in th leading cause of death for men and women ages in 2004 Approximately 10,600 HIV-infected NC residents were unaware of their status in 2005 Approximately 10,600 HIV-infected NC residents were unaware of their status in 2005 HIV incidence in the US and NC is stable or increasing HIV incidence in the US and NC is stable or increasing NC ranked 2nd in the US for the number of AIDS cases from non-metropolitan areas NC ranked 2nd in the US for the number of AIDS cases from non-metropolitan areas

33 New Patients in the UNC ID Clinic The median CD4 count was 202 cells/mm3 for patients initiating HIV care. The median CD4 count was 202 cells/mm3 for patients initiating HIV care. Majority (68%) initiated HIV care within 1 year of their first positive HIV test. Majority (68%) initiated HIV care within 1 year of their first positive HIV test. 75% met guidelines for starting HIV treatment at their first visit. 75% met guidelines for starting HIV treatment at their first visit. NC DHHS- HIV/STD Prevention & Care Branch

34 HIV viremia during early infection HIV RNA (plasma) HIV Antibody HIV p24 Ag 1622 Ramp-up viremia DT = 21.5 hrs 1 st gen 2 nd gen 3 rd gen p24 Ag EIA - HIV MP-NAT - HIV ID-NAT - Peak viremia: gEq/mL blip viremia Viral set-point: gEq/mL

35 Primary HIV-1 Infection Time in Years Infection CD4 Cells Early Opportunistic Infections Late Opportunistic Infections

36 Earlier HIV Diagnosis Allows prompt entry into care Allows prompt entry into care Initiation of ART prior to CD4 decline <200 improves mortality and morbidity Initiation of ART prior to CD4 decline <200 improves mortality and morbidity Management of STIs and other illness Management of STIs and other illness Short-term behavioral changes can have a large impact on HIV spread Short-term behavioral changes can have a large impact on HIV spread Improve natural history of disease with treatment during acute HIV infection? Improve natural history of disease with treatment during acute HIV infection?

37 Public Health Benefit Acute HIV is the most infectious period Acute HIV is the most infectious period HIV RNA levels in the genital tract correspond to HIV RNA levels in the blood HIV RNA levels in the genital tract correspond to HIV RNA levels in the blood Diagnosis is often missed even when patients are symptomatic with acute HIV infection Diagnosis is often missed even when patients are symptomatic with acute HIV infection

38 Plasma Viral Load and HIV Transmission Risk Rakai (Uganda) 453 HIV-disc. couples 11.6 % TR / year < '000 10' '000 >50000 HIV-RNA load (cp/ml) % partners infected Quinn 2000, NEJM 342:921

39 Wawer, et al, JID 2005, 191:1403

40 Viral Loads at Initial Detection Pilcher C et al. N Engl J Med 2005;352: Established HIV+ (n=66) Log HIV RNA cp/ml Median Viral Loads 29, ,183 Acute HIV+ (n=21)

41 HIV transmission prob. per male-female act: fold-change relative to wk 16 ( calculated after Chakraborty H, et al AIDS 2003) Weeks from Testing Positive for AHI Fold-change vs. wk

42 Risk of Transmission HIV RNA in Semen (Log 10 copies/ml) Risk of Transmission Reflects Genital Viral Burden (1/30- 1/200) (1/ /10,000) (1/ /2000) (1/100- 1/1000) Acute Infection Asymptomatic Infection HIV Progression AIDS

43 Further Evidence That Primary HIV Infection Accounts for a Large Proportion of HIV Transmission Source: ISSTDR, 2007

44 Public Health Benefit Identify HIV transmission networks Identify HIV transmission networks Allows real time prevention with index case and partners Allows real time prevention with index case and partners Awareness of HIV status has been associated with decreased sexual risk behaviors Awareness of HIV status has been associated with decreased sexual risk behaviors

45 Lessons for Public Health Acute HIV infection may be unexpectedly prevalent in common clinical scenarios Acute HIV infection may be unexpectedly prevalent in common clinical scenarios Immediate rather than deferred testing is key Immediate rather than deferred testing is key –HIV ELISA and HIV RNA Sexual partners of acutely HIV infected individuals are at a markedly increased per-act risk of acquiring HIV Sexual partners of acutely HIV infected individuals are at a markedly increased per-act risk of acquiring HIV

46 Lessons for Public Health Linkage of acute HIV diagnosis with Emergent ID Consultation is paramount Linkage of acute HIV diagnosis with Emergent ID Consultation is paramount –Interpretation and counseling on test results –Extensive counseling of newly diagnosed patient –Facilitate linkage to care and services –Consideration of ART for interested patients Acutely infected individuals provide public health officials with a unique opportunity to understand complex sexual networks Acutely infected individuals provide public health officials with a unique opportunity to understand complex sexual networks

47 Screening and Tracing Active Transmission (STAT) Program Total Tests (publicly-funded clinics) 107,733118,998128,708140,100 Antibody positive Antibody negative, RNA+ (acute)

48 November 1, 2002 – May 28, 2008 TOTAL Number of True RNA Positives Number of Community Index Cases (acute and recent)

49 Case Count (Burke, Franklin, Pitt, Henderson, Onslow, Martin) 3 (Buncombe, New Hanover) 4 (Robeson) 8 (Cumberland) 12 (Forsythe, Guilford) 15 (Wake) 15 (Mecklenburg) STAT Acutes by County (11/1/2002-2/1/2008) H H Duke University Hospital UNC Hospitals H H

50 Testing Site November May 2005 Tests Ab+ AHI (%) % of AHI HIV CTS 18, (2.9) 21 STD 117, (4.9) 48 FP 47, Prenatal/OB 47, (4.9) 3 Prison/Jail 7, (6.6) 7 Other 37, (3.9) 22

51 The STD/HIV Connection Susceptibility: – Genital ulcers provide portal of HIV entry – Non-ulcerative STDs increase target cells – STD treatment has been shown to slow the spread of HIV infection (individual & community) Infectiousness: – Presence of another STD increases amount of HIV in genital secretions – Treating STDs in PWHIV decreases the amount of HIV they shed how often they shed the virus

52 Potential impact of STI co-infection on detection of AHI HIV/STI Co-Infection Event week 1 week 2 week 3week 4 GC Trichomoniasis Chlamydia Syphilis HSV ARS Symptoms 3 rd gen. EIA HIV RNA + 4 th gen. EIA McCoy 0-014

53 STI Co-infections 23 clients (30%) had a concurrent STI STD TypeN(%) Men (n=13) Women (n=10) Gonorrhea9(39)7(54)2(20) Trichomoniasis5(22)0(0)5(50) Syphilis4(17)4(31)0(0) Herpes3(13)2(15)1(10) Chlamydia3(13)1(8)2(20) Bacterial vaginosis3(13)--3(30) GUD, unspecified1(4)1(8)0(0) Other reported STD-related sx5(7)4 1(6) McCoy 0-014

54 STI Co-infections by Race, Gender, and Risk Category p = 0.03 MSMMale HeteroFemale STI Co-infection McCoy 0-014

55 Missed Opportunities in STD Clinics HIV testing not offered to all Risk factors for HIV either not obtained or not recognized HIV testing not integrated into STD services Primary HIV Syndrome unrecognized by patients and clinicians Diagnostic test for Acute HIV Infections is not ordered

56 NC HIV Testing in STD Clinics HIV testing to be offered to all STD clients for each new visit regardless of when last HIV test performed DHHS policy to offer opt-out HIV testing 2005 estimate ~52% of NC STD clinic clients tested for HIV Wake County ( 2 nd largest STD clinic in North Carolina) with ~80-85% with universal offering of HIV testing. Wake County HIV testing increased to ~90% with opt-out approach

57 Acute HIV and North Carolina STAT

58 Duke-UNC Acute HIV Infection Research Consortium Research opportunities for patients with Acute and Recent HIV Infection: 1)Treatment of Acute HIV Infection with Once Daily Atripla (24 month treatment study which supplies Atripla) 2)Longitudinal Assessment of Acute/Recent HIV Infection (Adds to limited scientific knowledge currently available regarding acute/recent infection)

59 Duke-UNC Acute HIV Infection Research Consortium 3) CHAVI 001: Acute HIV-1 Infection Prospective Cohort Study Acquire information to develop an HIV vaccine The most relevant information may come from people with acute HIV infection and their partners

60 CHAVI Index Cases by County of Residence, 6/2007-2/2008 n=18 U D WakeGuilfordForsythe Key D Duke University Hospital U UNC Hospital 2 Cumberland Durham 1 1 Halifax 1 Pitt 1 Randolph 1 Martin

61 Key CHAVI Partners By County of Residence, 6/2007-2/2008 n=58 U D Duke University Hospital UNC Hospitals D U Mecklenburg Forsythe Guilford Durham Wake Cumberland Other Partner Locations NC: 3 SC: 1GA: 2 WA: 1 Abroad: 2 Unk: 6 Hertford 1 1 Bertie Martin 1 Scotland 1 Northampton 1 1 Craven Harnett 1 Pasquotank 1 Granville 1 Lee 1

62 Advatages to Dx and Care of AHI 1.An HIV diagnosis per se results in subsequent risk reduction 2. Initiation of HAART to reduce plasma and hence genital viral load thus reducing transmission potential 3. As we identify more undiagnosed HIV+ and more are successfully placed on HAART, transmission will shift even more to AHI 4. As frequency of HIV testing increases, we will idenitfy more AHI 5.Opportunity for short term behavior change (period of high infectivity of weeks)

63 Conclusion Make HIV testing routine Opt-out HIV Testing for all STD clients Screen all STD clients for AHI Include AHI in the Differential Dx of Acute Viral Syndrome in all Sexually Active Adults

64 Conclusion AHI is a true Public Health Emergency! AHI detection and case investigation puts identification of HIV at leading edge of transmission Opportunity for both early diagnosis and prevention Report all AHI cases within 24 hrs

65 laboratory

66 Given this VL distribution: Analytical vs. Clinical Sensitivity LL, cp/mlAb- HIV N=58 Se (Ab-)All HIV N=1437 Se (all) Ab only

67 Requirement for Analytical Sensitivity is Less Stringent than for VL Monitoring To be recommended as part of (all) general HIV testing, a NAAT would likely need ~95% detection at viral loads the equivalent of 5,000 to 10,000 HIV RNA copies per mL Better sensitivity required for effective analysis of pooled specimens

68 Acute HIV infections (first 2-3 months) are estimated to account for as much as half of all HIV transmission (Wawer at al JID 2005) They represent 0-10% of detectable infections presenting for HIV testing Real-time recognition of acute infections creates opportunities for highly targeted treatment, prevention and surveillance activities Detection of Acute HIV

69 Detuned assays can identify recent seroconversion, but with a 1-2 month delay from infection. These also do not identify additional cases over routine antibody tests. Real-time diagnosis of acute HIV depends on the identification of HIV antigens (e.g., p24) or nucleic acids (NAAT) in the absence of HIV antibodies. Detection of Acute HIV

70 HIV NegativeEstablished HIV Positive Ab screen NAAT screen Possible Acute HIV - The Gold Standard for Acute Screening is RNA Group Testing of Ab - Specimens Ab confirm + - Pilcher, CD et al. JAMA 2002;288:

71 NAAT is highly sensitive and with pooling, may be made specific. However, even pooled NAAT may be inefficient in high prevalence areas (>5%) and is technically demanding. Fourth generation HIV ELISAs detect both antigen and antibody simultaneously –Easy to perform –Equipment available in most HIV laboratories Testing to Identify Acute HIV

72 Window Periods for HIV Tests Stekler J. et al CID 2007

73 Ricardo da Silva de Souza – August 2006 Commercial Assays Comparative Timing of Detection of Acute HIV Infection = combined antigen-antibody= immunometric = Class specific antibody capture = antiglobulin / indirect Source HPA -UK

74 Reducing time to case identification

75 Summary: Pooling vs. Individual NAAT Pooled screening (even with minipools) makes testing possible by reducing costs and improving predictive value More complex but more efficient for through put and cost Single specimen NAAT screening should be reserved for situations where the pre-test likelihood of acute HIV infection is >/= 1% (e.g., suspected AHI, ?ED/urgent care screening)

76 Opportunities for New Technologies and Approaches Need to reduce time to identification of AHI NC median time to identification is ~9D Fast Track can reduce time to 2-4 days Current POC HIV tests only test for Ab 4 th generation EIA can reduce time to Dx and reduce cost Strategy may need to combine individual NAAT or discrepant POC 3 rd generation EIA to identify AHI

77 Rapid Antibody Testing The Good Makes testing feasible in non-traditional settings –Highly effective for outreach situations (needle exchange, bathhouse testing, street-corner outreach) Increases receipt of positive HIV test results –Where HIV results notification (PCRS) not in place May increase requests for HIV testing The Not So Good Confidentiality Cost 2-3x ELISA Ab tests May defer resource allocation/personal to HIV negatives May miss AHI Requires Confirmation

78 Alternative Approaches North Carolina AHI referral network Educate community providers about AHI Educate high risk community about AHI Linkage of ED testing to ID clinic and local health departments…… strongly encourage partnerships. EDs will test if burden for referral to care is met. Raise awareness of 3 rd generation EIA +/ WB I as possible AHI

79 Cost-effectiveness of the STAT Program: Decision Tree Analysis The expected savings from averting new HIV cases offset 22% of the testing costs Overall cost per QALY of $4,345 Conclusion: the program appears to be well below the cost effectiveness threshold of $50,000 which is often used as an indicator of good public health investment opportunities in the US. Still, cost a barrier for new programs

80 Targeting NAAT Screening by Site Over 2 years, at 135 public testing sites in NC, 325 acute and recent infections were identified among 224,124 testing clients ( 66% females, 4% MSM) Only 1/3 acute clients had HIV symptoms at testing There were no cases in 48 of 100 counties Targeted Screening: If NAAT used only in HIV C&T, STD, prison, and field visit sites in counties with 1 case, 95.4% of acute cases identified testing only 54.0% of the population with NAAT Testing only in STD clinics identified 40.1% of cases while testing 41.4% of the population.

81 Targeting is necessary; but be wary of preconceptions It is possible to construct a targeting algorithm for NAAT testing based on knowledge of local incidence, prevalence and individual risk factors associated with having recent infection Detuned test results can be used to develop NAAT targeting criteria A priori assumptions about who to test with NAAT are likely to be incorrect (i.e., limiting testing to only high risk clinics, or to symptomatic clients would be counterproductive)

82 Opportunities for New Approaches Need to reduce time to identification of AHI NC median time to identification is ~9D Fast Track can reduce time to 2-4 days We are implementing Fast track to all STD clinics based on symptoms and requiring STAT clinician approval

83 Fast Track Targeted AHI Testing : 1.Screen all clients for HIV Ab 2.Target Problem: Which symptoms (fever?) What time period (2-4 wks)? What duration ( >2 days)? Symptoms at best will detect 40% - Targeted testing Risk based ( i.e. MSM, anal/vaginal sex in past 2 weeks,etc ) Symptoms based (Fever + for >2 days within past 4 weeks) Site based ( prevalence 0.5% or type STD,CTS, etc.) 3. Need for further research to define symptom screen and develop predictive models for targeted AHI testing

84 Opportunities for New Technology Current POC HIV tests only test for Ab 4 th generation EIA can reduce time to Dx and reduce cost Plan to do real time side by side comparison of NAAT pooling with 4 th generation assay May need to combine individual NAAT or discrepant POC 3 rd generation EIA to identify AHI

85 Biology

86 Determining the Genetic Linkage of HIV-1 Subtype B Transmission Pairs: Analyses of Viral env Sequences From Donor and Recipient Jeffrey A. Anderson, MD-PhD University of North Carolina

87 Background A genetic bottleneck occurs during mucosal transmission, resulting in a subset of viruses responsible for transmission of HIV. DONOR RECIPIENT

88 Background Determining the genetic composition of the transmitted virus is critical to developing insight into disease progression, HIV pathogenesis, and candidate vaccines. Key questions: –From the donor quasispecies, what are the properties of the specific variant(s) being transmitted? –Are genital tract secretions a separate compartment from blood plasma?

89 135 D3 81 R3 ELISAWB # of env amplicons blood 148 D2 40 R2 174 D1 150 R1 3 MSM Transmission pairs from CHAVI 001: Donor vs. Recipient Sampling Time Weeks Post-infection Chronic Fiebig 1/2 Fiebig 5/ # of env amplicons semen Stage 22++Chronic NA + Fiebig 1/2 Fiebig 5/ Chronic Fiebig 1/2 Fiebig 5/

90 Experimental design Identify patients with acute HIV-1 infection, and sexual partners through contact tracing After informed consent, obtain blood plasma and semen/cervicovaginal lavage Isolate HIV-1 viral RNA from blood/semen/CVL fluid Generate a copy of the viral DNA and amplify by PCR Direct DNA sequence analysis to determine characteristics of HIV

91 Chromatograms from a single DNA sequence

92 Donor env blood plasma populations are heterogeneous D1D2D3

93 Recipient env blood plasma populations are homogeneous R1R2R3 22 identical sequences identical sequences

94 Phylogenetic analysis of D1/R1 1.Blood and semen populations are well-mixed

95 Phylogenetic analysis of D1/R1 1.Blood and semen populations are well-mixed 2.However, a subset of duplicated semen amplicons suggests selective outgrowth * * * * * *

96 Phylogenetic analysis of D1/R1 1.Blood and semen populations are well-mixed 2.However, a subset of duplicated semen amplicons suggests selective outgrowth 3.No blood amplicons were duplicated * * * * * * Blood Semen UniqueDuplicate P <

97 Phylogenetic analysis of D1/R1 1.Blood and semen populations are well-mixed 2.However, a subset of duplicated semen amplicons suggests selective outgrowth 3.No blood amplicons were duplicated * * * * * * Blood Semen UniqueDuplicate P < R1 is clearly genetically linked to D1 semen (99% nt identity), and did not arise from a duplicated semen sequence

98 Summary Genetic linkage of 3 subtype B transmission pairs was confirmed by SGA and DNA sequence analysis. All donor (D1-D3) populations had heterogeneous env populations, although D1 had low heterogeneity. A single variant was transmitted to each recipient (R1-R3). Semen populations were well-dispersed among blood populations. Clusters of duplicated sequences in semen of D1 and D3 suggest outgrowth of specific variants. These data suggest that semen sequences, in general, represent sequences present in blood; however, semen populations can be disrupted by selective outgrowth. Analyses of additional transmission pairs are ongoing and will lead to a greater knowledge of: –compartmentalization of viral sequences within semen vs. blood –the specific viral variant(s) transmitted from donor to recipient –viral sequences important for HIV-1 vaccine design

99 Acknowledgments Ron Swanstrom and lab members Beatrice Hahn Brandon Keele Jesus Salazar Susan Fiscus and lab Julie Nelson Myron Cohen Lihua Ping Kristen Dang and Christina Burch CHAVI 001 Clinical Core NC Dept. of Health and Human Services DIS Training Program and Officers

100

101 27 individuals (12%) were in closely related (<1% divergence) clusters Still, a 4-6 week period accounts for 10-15% of Transmission Frost s et al. CROI 2007 North Carolina may have lower attribution of AHI on Transmission

102 Network Analysis: Project SNAP Acutely/Recently infected MSM and high risk HIV-negative men recruited for in- depth ACASI interview and qualitative interview Respondent driven sampling to derive sexual and social network (2 generations) Better understanding of network formation, HIV/STD transmission, sex partner selection and Internet use among NC MSM

103

104

105

106 If you have an STD, Get Tested for HIV. Early Detection is Best! Learn to Recognize IT. Tell a Friend. Acute HIV is Easily Misdiagnosed. IT CAN BE MISTAKEN FOR COMMON ILLNESSES Common Symptoms of Acute HIV: High Fever Rash Fatigue Swollen Glands Sore Throat Nausea/Vomiting Night Sweats Symptoms usually appear about 2 weeks after exposure What Puts You At Risk? Unprotected Sex Sharing Needles The Acute HIV Program If you suspect you may have Acute HIV, get tested at your Local Health Department or at your doctors office. FREE Screening for acute HIV is done on all HIV tests done through the NC Health Departments Screening for acute HIV can be done at your doctors office – ask for an HIV RNA test in addition to the standard HIV antibody test.

107 Conclusions HIV antibody screening is a necessary first step in targeting prevention activities Assays able to detect antibody-negative infections should be incorporated into current HIV screening/testing NAAT may not be reasonable for low-risk routine screening in well patients and low prevalence populations Models for establishing criteria for targeting NAAT are need 4 th generation EIAs may present an alternative for diagnosis of acute HIV infection and merit urgent large-scale clinical evaluations

108 Window Periods for HIV Tests Stekler J. et al CID 2007

109 Tests to DX HIV Antibody ELISA$47 Western Blot$212 p24 Antigen$38 Individual HIV RNA PCR$218


Download ppt "Acute HIV and the North Carolina STAT Project Past, Present and Future Peter Leone, MD Associate Professor of Medicine University of North Carolina Medical."

Similar presentations


Ads by Google